Beyond Topicals: The Emerging Role of Oral Therapies in Psoriasis & Melasma

Abstract

The therapeutic landscape for chronic dermatologic disorders such as psoriasis and melasma has historically centered around topical agents. However, the limitations of topicals—ranging from inadequate efficacy in moderate-to-severe disease to issues with adherence—have spurred the exploration and integration of oral therapies. Driven by advances in immunology, molecular dermatology, and pharmacology, oral agents now offer hope for improved disease control, quality of life, and long-term management. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, and risk factors for both diseases, before focusing on the pivotal role of oral therapies. We discuss mechanisms of action, clinical trial data, guideline recommendations, and the practical implications for clinicians treating psoriasis and melasma.

Introduction

Psoriasis and melasma represent chronic, relapsing dermatological conditions with significant psychosocial and clinical burden. While topicals remain first-line for mild cases, their limitations in recalcitrant, extensive, or recurrent disease necessitate alternative strategies. Oral therapies, once reserved for refractory cases, are now increasingly recognized as integral to comprehensive management. Recent advances in our understanding of immune pathways, melanogenesis, and systemic factors underpinning these conditions have led to the development and approval of novel oral agents. This article reviews the shifting paradigm from topical-centric to systemic, oral-based management for psoriasis and melasma, emphasizing recent scientific evidence and clinical guidelines.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-3% of the global population, with variable prevalence across ethnic and geographic lines. It is associated with substantial comorbidities, including psoriatic arthritis, metabolic syndrome, and cardiovascular disease. Melasma, though less prevalent, disproportionately impacts women of reproductive age and those with darker skin phototypes, particularly in Asian and Hispanic populations. Both conditions are associated with significant quality-of-life impairment, stigmatization, and psychiatric morbidity, underscoring the need for effective systemic therapies when topical regimens fail.

Pathophysiology

Psoriasis is a chronic, immune-mediated disorder characterized by dysregulated T-cell activation, cytokine overproduction (notably IL-17, IL-23, and TNF-α), and aberrant keratinocyte proliferation. This immune dysregulation results in the hallmark erythematous plaques. Melasma is primarily a disorder of hypermelanosis, influenced by UV radiation, hormonal factors, and genetic predisposition, with emerging evidence of a complex interplay between melanogenesis, oxidative stress, vascular factors, and inflammatory mediators. Recognition of these underlying mechanisms has informed the development of targeted oral therapies.

Risk Factors

Psoriasis risk factors include genetic predisposition (notably HLA-Cw6), environmental triggers (trauma, infections), metabolic syndrome, psychological stress, and certain medications. Melasma risk is heightened by UV exposure, hormonal fluctuations (pregnancy, oral contraceptives), genetic factors, and certain medications. The interplay of intrinsic and extrinsic factors in both diseases necessitates a multifactorial therapeutic approach, often requiring systemic intervention.

Clinical Features

Psoriasis manifests as well-demarcated, erythematous plaques with silvery scale, commonly on extensor surfaces, scalp, and trunk; nail and joint involvement may occur. Disease severity ranges from mild localized lesions to extensive, debilitating plaques. Melasma presents as symmetric hyperpigmented macules and patches, most frequently on sun-exposed facial areas. Both conditions are chronic and prone to relapse, posing ongoing management challenges.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by characteristic morphology and distribution; histopathology is reserved for atypical presentations. Assessment of disease severity incorporates body surface area (BSA), PASI score, and quality-of-life indices. Melasma diagnosis is likewise clinical, with Wood\"s lamp examination aiding in distinguishing epidermal from dermal involvement. Objective assessment tools, such as the Melasma Area and Severity Index (MASI), facilitate monitoring and therapeutic decision-making.

Treatment & Management

Topical corticosteroids, vitamin D analogues, and calcineurin inhibitors remain foundational in both diseases, but their efficacy is often limited in moderate-to-severe or recalcitrant cases. For psoriasis, phototherapy and systemic agents—including methotrexate, cyclosporine, and acitretin—have long been mainstays. Melasma management typically employs hydroquinone, azelaic acid, and other depigmenting agents, with limited lasting benefit in many cases. Systemic, oral therapies are increasingly deployed for extensive, refractory, or rapidly relapsing disease, offering deeper and more durable responses.

Recent Advances / Emerging Therapies

In psoriasis, the advent of targeted oral agents such as apremilast (a PDE4 inhibitor) and the development of TYK2 inhibitors (e.g., deucravacitinib) have revolutionized management, offering oral efficacy with favorable safety profiles compared to traditional immunosuppressants. Apremilast, in particular, modulates inflammatory cytokines without significant immunosuppression risk. For melasma, oral tranexamic acid has emerged as a promising adjunct, reducing melanogenesis via inhibition of plasminogen activation and subsequent vascular and inflammatory pathways. Early studies suggest efficacy in recalcitrant cases, although optimal dosing and duration remain under investigation. Antioxidants, such as oral polypodium leucotomos extract, and other agents like glutathione are also under study, though robust data are pending. The expanding armamentarium underscores a shift toward mechanism-based, individualized therapies.

Guideline Recommendations

Recent guidelines advocate for oral therapy in moderate-to-severe psoriasis unresponsive to topicals and phototherapy, or when disease significantly impairs quality of life. Apremilast is recommended as a first-line oral agent for suitable patients, with careful monitoring for gastrointestinal and mood-related adverse effects. Methotrexate remains a cost-effective option, with safety monitoring for hepatic and hematologic toxicity. In melasma, consensus guidelines suggest oral tranexamic acid as an adjunct for recalcitrant disease, with caution regarding thromboembolic risk and contraindications. Close monitoring and patient education are essential to optimize safety and adherence.

Conclusion

The evolving role of oral therapies in psoriasis and melasma reflects advances in disease understanding and pharmacologic innovation. While topicals remain indispensable, oral agents offer hope for patients with extensive, refractory, or relapsing disease. Evidence supports their efficacy and safety when judiciously selected and monitored. Ongoing research and guideline updates will further refine their use, underscoring the importance of individualized, mechanism-based management strategies in chronic dermatologic care.